US 12,441,979 B2
Akkermansia muciniphila strain and use thereof
Gwang Pyo Ko, Seoul (KR); Hyo Shin Yoon, Gangneung-si (KR); Chung Hwan Cho, Gwangmyeong-si (KR); Hyun Ju You, Incheon (KR); and Tae Wook Nam, Seongnam-si (KR)
Assigned to KOBIOLABS, INC., Seoul (KR)
Appl. No. 17/279,247
Filed by KoBioLabs, Inc., Seoul (KR)
PCT Filed Oct. 11, 2019, PCT No. PCT/KR2019/013402
§ 371(c)(1), (2) Date Mar. 24, 2021,
PCT Pub. No. WO2020/076136, PCT Pub. Date Apr. 16, 2020.
Claims priority of application No. 10-2018-0121137 (KR), filed on Oct. 11, 2018; and application No. 10-2019-0125670 (KR), filed on Oct. 10, 2019.
Prior Publication US 2022/0002665 A1, Jan. 6, 2022
Int. Cl. A61K 38/16 (2006.01); A23L 33/00 (2016.01); A23L 33/135 (2016.01); A61K 35/74 (2015.01); A61K 38/48 (2006.01); A61P 3/04 (2006.01); A61P 3/08 (2006.01); C12N 1/20 (2006.01); C12R 1/01 (2006.01)
CPC C12N 1/205 (2021.05) [A23L 33/135 (2016.08); A23L 33/40 (2016.08); A61K 35/74 (2013.01); A61K 38/482 (2013.01); A61P 3/04 (2018.01); A61P 3/08 (2018.01); C12Y 304/21102 (2013.01); A23V 2002/00 (2013.01); C12R 2001/01 (2021.05)] 3 Claims
OG exemplary drawing
 
1. A method of suppressing appetite or treating metabolic diseases associated with glucagon-like peptide-1 (GLP-1), comprising administering a composition comprising Akkermansia muciniphila SNUG-61027 strain with accession number KCTC 13530BP to a subject in need thereof.